Publication: Results of the acceptability & feasibility study of the BPaL regimen

A study, conducted by KNCV Tuberculosis Foundation and TB Alliance, shows that the adoption of BPal will be accepted and feasible in the three high drug-resistant tuberculosis (DR-TB) burden countries; Indonesia, Kyrgyzstan and Nigeria. BPal is a 6 month oral regimen composed of bedaquiline, pretomanid and linezolid for treating extensively drug-resistant tuberculosis (XDR-TB) and is a potential alternative for at least 20 months of individualized treatment regimens (ITR) – which has low tolerability, treatment adherence and success rates.

According to the study, published in the peer reviewed BMC Journal, BPaL could increase the treatment success rate and alleviate the individual and health care system burden of DR-TB. The majority is willing to start using BPaL as the standard of care for eligible patients despite country-specific health system constraints.

The publication ‘Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients’ can be found here.

Click here to view other KNCV publications.

KNCV has been fighting TB since its establishment in 1903. Over the past 117 years, the organization has acquired indispensable knowledge and experience in the field of effective TB control, resulting in pre-elimination in the Netherlands and significant contributions to global evidence generation, policy development and TB program implementation worldwide.

Our experts
KNCV governance framework
Our patroness
Partner with us

Tuberculosis is still one of the major causes of preventable death in the world and claims over 4000 lives a day, leading to over 1,5 million deaths a year.

Patient stories

The story of Abdurahim
The story of Fikeraddis
The story of Issayas
The story of Zarina
The story of Maxine
The story of Saanvi

Address

KNCV Tuberculosefonds
Maanweg 174
2516 AB Den Haag
+31 70 416 7222

OPEN IN GOOGLE MAPS

Postal address

Postbus 146
2501 CC Den Haag

More information

Sorry

De versie van de browser die je gebruikt is verouderd en wordt niet ondersteund.
Upgrade je browser om de website optimaal te gebruiken.